Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer

被引：0
|
作者：
Tan, W. L. [1 ]
Tan, S. H. [1 ]
Tan, D. S. W. [1 ]
Lai, G. G. Y. [1 ]
Ang, M. -K. [1 ]
Jain, A. [1 ]
Kanesvaran, R. [1 ]
Rajasekaran, T. [1 ]
Saw, S. P. L. [1 ]
Teh, Y. L. [1 ]
Chan, J. [1 ]
Ng, Q. S. [1 ]
Lim, D. W. -T. [1 ]
机构：
[1] Natl Canc Ctr Singapore, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
EGFR-mutated NSCLC; First-line Osimertinib; Asian patients;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-31
引用
收藏
页码：S652 / S653
页数：2
相关论文
共 50 条
  • [31] Adjuvant therapy with Osimertinib in resectable EGFR-mutated lung cancer
    Gassa, Asmae
    Ozkan, Filiz
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2021, 27 (02): : 172 - 173
  • [32] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
    Aguilar-Serra, J.
    Gimeno-Ballester, V
    Pastor-Clerigues, A.
    Milara, J.
    Trigo-Vicente, C.
    Cortijo, J.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 637 - 646
  • [33] cost-effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer
    Zhang, Huahua
    Zheng, Xiaochun
    Zhang, Yandong
    Wang, Jiangfeng
    FUTURE ONCOLOGY, 2024,
  • [34] The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer
    Motta-Guerrero, Rodrigo
    Recondo, Gonzalo
    Cardona, Andres
    Corrales, Luis
    Arnao, Veronica
    Failoc-Rojas, Virgilio E.
    Aliaga, Carlos
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 196
  • [35] Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer
    Santarpia, Mariacarmela
    Menis, Jessica
    Chaib, Imane
    Cao, Maria Gonzalez
    Rosell, Rafael
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 831 - 840
  • [36] Osimertinib as first-line treatment for recurrent lung cancer patients with EGFR mutation
    Osoegawa, Atsushi
    Karashima, Takashi
    Takumi, Yohei
    Sato, Takahiro
    Abe, Miyuki
    Hashimoto, Takafumi
    Sugio, Kenji
    JOURNAL OF THORACIC DISEASE, 2023, 15 (10) : 5566 - 5573
  • [37] Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Gray, Jhanelle E.
    Okamoto, Isamu
    Sriuranpong, Virote
    Vansteenkiste, Johan
    Imamura, Fumio
    Lee, Jong Seok
    Pang, Yong-Kek
    Cobo, Manuel
    Kasahara, Kazuo
    Cheng, Ying
    Nogami, Naoyuki
    Cho, Eun Kyung
    Su, Wu Chou
    Zhang, Guili
    Huang, Xiangning
    Li-Sucholeiki, Xiaocheng
    Lentrichia, Brian
    Dearden, Simon
    Jenkins, Suzanne
    Saggese, Matilde
    Rukazenkov, Yuri
    Ramalingam, Suresh S.
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 6644 - 6652
  • [38] Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced EGFR-Mutated Non-Small-Cell Lung Cancer in the First-Line Setting?
    Tanaka, Tomohiro
    Ishiki, Hiroto
    Kubo, Emi
    Yokota, Sayuri
    Shimizu, Masaki
    Kiuchi, Daisuke
    Satomi, Eriko
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (08) : 843 - +
  • [39] Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
    Calvo, Emiliano
    Lee, Jong-Seok
    Kim, Sang-We
    Moreno, Victor
    deCastro Carpeno, Javier
    Weilert, Doris
    Laus, Gianluca
    Mann, Helen
    Vishwanathan, Karthick
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (08): : 1099 - 1109
  • [40] Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
    Saw, Stephanie P. L.
    Low, Yi Fen
    Lai, Gillianne G. Y.
    Chan, Landon L.
    Wong, Wesley K. Y.
    Tsui, Giselle
    Chen, Olivia H.
    Seet, Amanda O. L.
    Tan, Wei Chong
    Tan, Aaron C.
    Chan, Johan W. K.
    Teh, Yi Lin
    Tan, Wan -Ling
    Ng, Quan Sing
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Lim, Darren W. T.
    Tan, Daniel S. W.
    Mok, Tony S. K.
    Li, Molly S. C.
    LUNG CANCER, 2024, 193
12345